VKTX Dividend: Viking Therapeutics Inc Yield Insights

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	52	49	37	16	10	10
Research & Development	222	101	63	54	44	31
Operating Expenses	274	150	100	70	55	42
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-237	-109	-85	-68	-54	-39
Income Tax Expense	--	--	--	--	--	--
Net Income	-237	-109	-85	-68	-54	-39
Net Income Growth	139%	28%	25%	26%	38%	56%
Shares Outstanding (Diluted)	112.32	109.03	94.34	76.83	77.2	72.6
Shares Change (YoY)	1%	16%	23%	0%	6%	1%
EPS (Diluted)	-2.11	-1	-0.91	-0.9	-0.71	-0.54
EPS Growth	138%	11%	1%	27%	31%	50%
Free Cash Flow	-224	-87	-73	-48	-47	-21
Free Cash Flow Per Share	-1.99	-0.79	-0.77	-0.62	-0.6	-0.28
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	--	-150	-100	--	--	--
EBITDA Margin	--	0%	0%	--	--	--
D&A For EBITDA	--	0	0	--	--	--
EBIT	-274	-150	-100	-70	-55	-42
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	--	--	--	--	--

Viking Therapeutics Inc (VKTX) Price